Data To Be Presented At MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting Underscore Teva Pharmaceutical Industries Limited (TEVA)’s Commitment To Developing Solutions To Meet The Needs Of The Multiple Sclerosis Community
9/3/2014 10:16:49 AM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that more than 20 company-sponsored abstracts including data on COPAXONE® (glatiramer acetate injection) and laquinimod, an investigational therapy for multiple sclerosis (MS), will be featured at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, September 10 – 13, 2014.
“Teva takes pride in its well-established presence in the MS community and on-going efforts to bring convenient, effective therapies to those living with this disease,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries, Ltd. “The data being presented at this year’s joint ACTRIMS-ECTRIMS meeting continues to demonstrate our commitment to researching and developing new treatment options to benefit and meet the needs of this diverse patient population.”
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by